Medical News

RSS

EMSC and State of Idaho to provide medical transportation management services for Medicaid beneficiaries

Emergency Medical Services Corporation today announced that its American Medical Response subsidiary has entered into a new agreement with the State of Idaho to provide non-emergency medical transportation management services for the State's Medicaid beneficiaries.

30 Apr 2010

EndoChoice granted FDA marketing clearance for BONASTENT Esophageal and Biliary Stent platforms

EndoChoice, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its BONASTENT® Fully Covered Esophageal Stent for the treatment of malignant esophageal obstructions, and its BONASTENT Uncovered Biliary Stent for the treatment of malignant biliary obstructions.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010

BioTime to acquire Singapore-based company, ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd.

30 Apr 2010

Dismal figures for Victorian public hospital performance in 2009, says report

A new report regarding performances of hospitals has come up with disturbing facts. This Your Hospitals report (July to December 2009) released yesterday revealed;

29 Apr 2010

A crystal ball into your future health!

Imagine knowing just what diseases you are likely to suffer from in your lifetime thanks to the sequencing of your genes. That is exactly what Professor Stephen Quake knows, because he has had his entire genome sequenced and studied. In fact he was in the news last year as well when he used new technology to sequence his genetic code for less than $50,000.

29 Apr 2010

Hullabaloo over the tobacco tax hike and planned plain cigarette packaging law

The Australian Federal Government this week announced an increase in taxes by 25% on cigarettes to discourage smoking and generate funds for more antismoking measures. In a new development Federal Opposition Leader Tony Abbott announced that the Coalition will support this move.

29 Apr 2010

ZOLL Medical's second-quarter revenues up 15% to $107.1 million

ZOLL Medical Corporation, a manufacturer of resuscitation devices and software solutions, today announced that revenues for the second quarter of fiscal 2010 increased 15% to $107.1 million, compared to revenues in the second quarter of last year of $92.7 million. Revenue results included a positive foreign exchange impact of approximately $2.2 million, compared to the second quarter of fiscal 2009.

29 Apr 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

Bavarian Nordic A/S announced today that PROSTVAC™ has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for its proposed use in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

29 Apr 2010

Idenix Pharmaceuticals prices underwritten offering of common stock at $4.35 per share

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten offering of 6,460,672 shares of its common stock at a price of $4.35 per share. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $26.2 million. All of the shares are being sold by Idenix.

29 Apr 2010

NeoGenomics first-quarter revenue up 22%

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter 2010.

29 Apr 2010

SDI reports increase in hospital outpatient surgical visits in 2009

SDI, a leading healthcare market insight and analytics firm, today reported that the number of hospital outpatient surgical visits increased 4.5% in 2009 compared with 2008. The number of hospital inpatient visits with surgical procedures, however, remained relatively unchanged in 2009.

29 Apr 2010

EMSC generates net revenue of $679.4 million for first-quarter 2010

Emergency Medical Services Corporation today announces results for the first quarter ended March 31, 2010.

29 Apr 2010

Orion Health Rhapsody Integration Engine to be deployed across Philips' healthcare informatics solutions

Royal Philips Electronics today announced an agreement with Orion Health™, a leading provider of integration solutions in healthcare, to deploy the Orion Health Rhapsody® Integration Engine across Philips' portfolio of healthcare informatics solutions.

From Philips Healthcare 29 Apr 2010

Nutraceutical International reports net sales of $47.9M for second-quarter fiscal 2010

Nutraceutical International Corporation today reported results for the fiscal 2010 second quarter ended March 31, 2010. Net sales for the fiscal 2010 second quarter were $47.9 million compared to $42.0 million for the same quarter of fiscal 2009. For the second quarter of fiscal 2010, net income was $5.1 million, or $0.49 diluted earnings per share, compared to a net loss of $(23.4) million, or $(2.15) per diluted share, for the same quarter of fiscal 2009.

29 Apr 2010